Inhibition of P70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells

Overview

Journal Mol Cancer Ther

Date 2015 Jan 10

PMID 25573956

Citations 14

Authors

Yan Zhang

Qing Wang

Li Chen

Hsin-Sheng Yang

Affiliations

Soon will be listed here.

Abstract

Agents targeting insulin-like growth factor 1 receptor (IGF-1R) are being actively examined in clinical trials. Although there has been some initial success of single-agent targeting IGF-1R, attempts in later studies failed because of resistance. This study aimed to understand the effects of programmed cell death 4 (Pdcd4) on the chemosensitivity of the IGF-1R inhibitor OSI-906 in colorectal cancer cells and the mechanism underlying this impact. Using OSI-906-resistant and -sensitive colorectal cancer cells, we found that the Pdcd4 level directly correlates with cell chemosensitivity to OSI-906. In addition, tumors derived from Pdcd4 knockdown cells resist the growth inhibitory effect of OSI-906 in a colorectal cancer xenograft mouse model. Moreover, Pdcd4 enhances the antiproliferative effect of OSI-906 in resistant cells through suppression of p70S6K1 activation. Knockdown of p70S6K1, but not p70S6K2, significantly increases the chemosensitivity of OSI-906 in cultured colorectal cancer cells. Furthermore, the combination of OSI-906 and PF-4708671, a p70S6K1 inhibitor, efficiently suppresses the growth of OSI-906-resistant colon tumor cells in vitro and in vivo. Taken together, activation of p70S6K1 that is inhibited by Pdcd4 is essential for resistance to the IGF-1R inhibitor in colon tumor cells, and the combinational treatment of OSI-906 and PF-4708671 results in enhanced antiproliferation effects in colorectal cancer cells in vitro and in vivo, providing a novel venue to overcome the resistance to the IGF-1R inhibitor in treating colorectal cancer.

Citing Articles

Adipose-derived exosomes ameliorate skeletal muscle atrophy via miR-146a-5p/IGF-1R signaling.

Qin M, Zhu J, Xing L, Fan Y, Luo J, Sun J J Nanobiotechnology. 2024; 22(1):754.

PMID: 39696303 PMC: 11657514. DOI: 10.1186/s12951-024-02983-7.

The Impact of Pdcd4, a Translation Inhibitor, on Drug Resistance.

Wang Q, Yang H Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459035 PMC: 11510623. DOI: 10.3390/ph17101396.

Platycodin D induces apoptosis through JNK1/AP-1/PUMA pathway in non-small cell lung cancer cells: A new mechanism for an old compound.

Chen S, Wang Q, Ming S, Zheng H, Hua B, Yang H Front Pharmacol. 2022; 13:1045375.

PMID: 36483740 PMC: 9723146. DOI: 10.3389/fphar.2022.1045375.

In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.

Wang Y, Huang X, Chen S, Jiang H, Rao H, Lu L Curr Oncol. 2022; 29(9):6573-6593.

PMID: 36135086 PMC: 9497598. DOI: 10.3390/curroncol29090517.

Dissecting the Roles of PDCD4 in Breast Cancer.

Cai Q, Yang H, Li Y, Zhu J Front Oncol. 2022; 12:855807.

PMID: 35795053 PMC: 9251513. DOI: 10.3389/fonc.2022.855807.

References

Jansen A, Camalier C, Colburn N . Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 2005; 65(14):6034-41. DOI: 10.1158/0008-5472.CAN-04-2119. View

Cmarik J, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H . Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A. 1999; 96(24):14037-42. PMC: 24186. DOI: 10.1073/pnas.96.24.14037. View

Fang J, Meng Q, Vogt P, Zhang R, Jiang B . A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability. J Cell Physiol. 2006; 209(2):261-5. DOI: 10.1002/jcp.20749. View

Carboni J, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W . BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther. 2009; 8(12):3341-9. DOI: 10.1158/1535-7163.MCT-09-0499. View

Schmid T, Jansen A, Baker A, Hegamyer G, Hagan J, Colburn N . Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res. 2008; 68(5):1254-60. DOI: 10.1158/0008-5472.CAN-07-1719. View

Pearce L, Alton G, Richter D, Kath J, Lingardo L, Chapman J . Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010; 431(2):245-55. DOI: 10.1042/BJ20101024. View

Mayo L, Donner D . The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002; 27(9):462-7. DOI: 10.1016/s0968-0004(02)02166-7. View

Yang H, Jansen A, Komar A, Zheng X, Merrick W, Costes S . The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol. 2002; 23(1):26-37. PMC: 140682. DOI: 10.1128/MCB.23.1.26-37.2003. View

Hakam A, Yeatman T, Lu L, Mora L, Marcet G, Nicosia S . Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 1999; 30(10):1128-33. DOI: 10.1016/s0046-8177(99)90027-8. View

10.

Mulvihill M, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D . Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 2011; 1(6):1153-71. DOI: 10.4155/fmc.09.89. View

11.

Zhao H, Desai V, Wang J, Epstein D, Miglarese M, Buck E . Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Mol Cancer Ther. 2011; 11(2):503-13. DOI: 10.1158/1535-7163.MCT-11-0327. View

12.

Ekyalongo R, Mukohara T, Kataoka Y, Funakoshi Y, Tomioka H, Kiyota N . Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line. Invest New Drugs. 2012; 31(2):293-303. DOI: 10.1007/s10637-012-9855-1. View

13.

Guo X, Li W, Wang Q, Yang H . AKT Activation by Pdcd4 Knockdown Up-Regulates Cyclin D1 Expression and Promotes Cell Proliferation. Genes Cancer. 2012; 2(8):818-28. PMC: 3278903. DOI: 10.1177/1947601911431082. View

14.

Fenton T, Gout I . Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol. 2010; 43(1):47-59. DOI: 10.1016/j.biocel.2010.09.018. View

15.

Flanigan S, Pitts T, Eckhardt S, Tentler J, Tan A, Thorburn A . The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res. 2010; 16(22):5436-46. PMC: 3119523. DOI: 10.1158/1078-0432.CCR-10-2054. View

16.

Yuen J, Macaulay V . Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets. 2008; 12(5):589-603. DOI: 10.1517/14728222.12.5.589. View

17.

Wang Q, Zhu J, Zhang Y, Sun Z, Guo X, Wang X . Down-regulation of programmed cell death 4 leads to epithelial to mesenchymal transition and promotes metastasis in mice. Eur J Cancer. 2013; 49(7):1761-70. PMC: 3625476. DOI: 10.1016/j.ejca.2012.12.014. View

18.

Leupold J, Yang H, Colburn N, Asangani I, Post S, Allgayer H . Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene. 2007; 26(31):4550-62. DOI: 10.1038/sj.onc.1210234. View

19.

Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B . The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997; 1332(3):F105-26. DOI: 10.1016/s0304-419x(97)00007-3. View

20.

Wang Q, Sun Z, Yang H . Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells. Oncogene. 2007; 27(11):1527-35. DOI: 10.1038/sj.onc.1210793. View